Corpus callosum axonal injury in multiple sclerosis measured by proton magnetic resonance spectroscopic imaging

Archives of Neurology

Volumn 61, Issue 7, 2004, Pages 1081-1086

  Oh, Joonmi ^a,c   Pelletier, Daniel ^b   Nelson, Sarah J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCSF Multiple Sclerosis Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE; CREATINE PHOSPHATE; N ACETYLASPARTIC ACID;

ADULT; ARTICLE; AXONAL INJURY; BRAIN LEVEL; BRAIN METABOLISM; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS CALLOSUM; CORRELATION ANALYSIS; HUMAN; IMAGE ANALYSIS; IMAGING SYSTEM; METABOLITE; MULTIPLE SCLEROSIS; NERVE FIBER TRANSECTION; NEUROIMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL DETECTION; WHITE MATTER;

ADULT; AXONS; CORPUS CALLOSUM; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; MULTIPLE SCLEROSIS; PROTONS; STATISTICS, NONPARAMETRIC;

EID: 3142746904     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.61.7.1081     Document Type: Article

References (25)

1. Bonavita S, Di Salle F, Tedeschi G. Proton MRS in neurological disorders. Eur J Radiol. 1999;30:125-131.
2. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetylaspartate with monoclonal antibodies. Neuroscience. 1991;45:37-45.
3. Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med. 1990;14:154-159.
4. Fu L, Matthews PM, De Stefano N, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain. 1998;121:103-113.
5. De Stefano N, Matthews PM, Fu L, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis: results of a longitudinal magnetic resonance spectroscopy study. Brain. 1998;121:1469-1477.
6. De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol. 2001;58:65-70.
7. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33:1444-1452.
8. 1H magnetic resonance spectroscopy of normal-appearing white matter in primary progressive multiple sclerosis. J Neurol. 1999;246:1023-1026.
9. Matthews PM, Pioro E, Narayanan S, et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain. 1996;119:715-722.
10. Hirsch JA, Lenkinski RE, Grossman RI. MR spectroscopy in the evaluation of enhancing lesions in the brain in multiple sclerosis. AJNR Am J Neuroradiol. 1996;17:1829-1836.
11. Narayanan S, Fu L, Pioro E, et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol. 1997;41:385-391.
12. Brex PA, Parker GJ, Leary SM, et al. Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations. J Neurol Neurosurg Psychiatry. 2000;68:627-632.
13. Brex PA, Gomez-Anson B, Parker GJ, et al. Proton MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis. J Neurol Sci. 1999;166:16-22.
14. Tourbah A, Stievenart JL, Gout O, et al. Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis. Neurology. 1999;53:1091-7.
15. Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain. 2000;123:1845-1849.
16. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-231.
17. Nelson SJ, Huhn S, Vigneron DB, et al. Volume MRI and MRSI techniques for the quantitation of treatment response in brain tumors: presentation of a detailed case study. J Magn Reson Imaging. 1997;7:1146-1152.
18. Nelson SJ. Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors. Magn Reson Med. 2001;46:228-39.
19. Noworolski SM, Nelson SJ, Henry RG, et al. High spatial resolution 1H-MRSI and segmented MRI of cortical gray matter and subcortical white matter in three regions of the human brain. Magn Reson Med. 1999;41:21-29.
20. Healy MP, McKnight TR, Priest D, Proctor EC, Dillon WP, Nelson SJ. MRS analysis of different regions of normal brains. Paper presented at The Proceedings of the 39th Annual Meeting of the American Society of Neuroradiology; April 2001; Boston, Mass.
21. Pelletier D, Nelson SJ, Grenier D, Lu Y, Genain C, Goodkin DE. 3-D echo planar (1)HMRS imaging in MS: metabolite comparison from supratentorial vs central brain. Magn Reson Imaging. 2002;20:599-606.
22. Pelletier J, Suchet L, Witjas T, et al. A longitudinal study of callosal atrophy and interhemispheric dysfunction in relapsing-remitting multiple sclerosis. Arch Neurol. 2001;58:105-111.
23. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338:278-285.
24. Miller BL, Chang L, Booth R, et al. In vivo 1H MRS choline: Correlation with in vitro chemistry/histology. Life Sci. 1996;58:1929-1935.
25. Sarchielli P, Presciutti O, Pelliccioli GP, et al. Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain. 1999;122:513-521.